Site icon pharmaceutical daily

2021 Pipeline Insights on the Postoperative Pain Industry – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Postoperative Pain – Pipeline Insight, 2021” drug pipelines has been added to ResearchAndMarkets.com’s offering.

This report provides comprehensive insights about 60+ companies and 60+ pipeline drugs in Postoperative pain pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Postoperative pain (CINV) are the side effects of cancer chemotherapy that can cause significant negative impacts on patients’ quality of life and on their ability to tolerate and comply with therapy. An estimated 80% of patients with cancer experience chemotherapy-induced nausea and vomiting. It includes emesis and nausea, which can involve a loss of appetite and result in decreased oral intake of fluids and calories. CINV can be classified into 5 types: acute, delayed, anticipatory, breakthrough, and refractory. The pathophysiology of CINV includes both peripheral and central nervous system (CNS) pathways with different mechanisms involved in acute CINV and delayed CINV. Risk factors for developing CINV can be classified as patient-related or treatment-related. Prevention is the primary goal in the management of CINV. The primary alternative for prevention and treatment include 5-HT3 receptor antagonists, NK1 receptor antagonists, and corticosteroids. Other medications used, but to a lesser extent, include dopamine antagonists, benzodiazepines, cannabinoids, and olanzapine.

“Postoperative pain – Pipeline Insight, 2021” report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Postoperative pain pipeline landscape is provided which includes the disease overview and Postoperative pain treatment guidelines. The assessment part of the report embraces, in depth Postoperative pain commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Postoperative pain collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

Postoperative pain Emerging Drugs Chapters

This segment of the Postoperative pain report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Postoperative pain: Therapeutic Assessment

This segment of the report provides insights about the different Postoperative pain drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Postoperative pain

There are approx. 60+ key companies which are developing the therapies for Postoperative pain. The companies which have their Postoperative pain drug candidates in the most advanced stage, i.e. Registered include, Heron Therapeutics.

The report covers around 60+ products under different phases of clinical development like

Postoperative pain pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Products have been categorized under various Molecule types such as

The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Key Questions Answered

Current Treatment Scenario and Emerging Therapies:

Key Players

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/wgdayp

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Exit mobile version